ERCM 2022
Recent articles
- Buprenorphine and Naloxone Sublingual Tablets Added to Portfolio
- New to Camber’s Portfolio: Losartan Potassium and Hydrochlorothiazide Tablets
- NACDS TSE 2026 Event Recap
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards